FTC: Cortisol Claims Defy Reality

October 6, 2004
The Federal Trade Commission has charged marketers of two dietary supplements with claiming, falsely and without substantiation, that their products can cause weight loss and reduce the risk of serious health conditions.

Cortislim • Cortislim Promoters Forfeit $4.5 Million in FTC Settlement • Weight Loss in a Bottle? Not Likely • FTC: Cortisol Claims Defy Reality • Lawsuit Challenges Cortislim Claims

According to the FTC's complaint, Los Angeles-area marketers Window Rock Enterprises, Inc. and Infinity Advertising, Inc., and product formulator Shawn Talbott have sold "CortiSlim" and "CortiStress" through a number of widely aired infomercials and short TV commercials, as well as radio and print advertisements and Internet Web sites.

"The Window Rock defendants' weight-loss and disease-prevention claims fly in the face of reality," said Lydia B. Parnes, Acting Director of the FTC's Bureau of Consumer Protection. "No pill can replace a healthy program of diet and exercise."

The FTC's complaint alleges that the Window Rock defendants violated the FTC Act by making deceptive claims for CortiSlim and CortiStress. In addition, the complaint alleges that the defendants violated the FTC Act by using a deceptive format in at least two of their infomercials to suggest falsely that the infomercials were independent television programs, rather than paid commercial advertising.

The complaint seeks permanent injunctive relief, including redress for consumers who purchased the products.

According to the FTC, the defendants began marketing CortiSlim in August 2003, through nationally disseminated infomercials featuring Talbott that aired on a number of television channels, including Access Television, Travel Channel, and Discovery Channel. The FTC alleges that the defendants promoted cortisol control as "the answer" for anyone who wants to lose weight, especially abdominal weight.

According to the FTC's complaint, the defendants' broadcast ads, print ads, and Web sites claimed that persistently elevated levels of cortisol, the "stress hormone," are the underlying cause of weight gain and weight retention and also claimed that CortiSlim effectively reduces and controls cortisol levels and thereby causes substantial weight loss.

The FTC alleges that the defendants claimed that CortiSlim:

(1) causes weight loss of 10 to 50 pounds for virtually all users;
(2) causes users to lose as much as 4 to 10 pounds per week over multiple weeks;
(3) causes users to lose weight specifically from the abdomen, stomach, and thighs;
(4) causes rapid and substantial weight loss;
(5) causes long-term or permanent weight loss; and
(6) causes weight loss.

The FTC also alleges that the defendants claimed that the effectiveness of CortiSlim and its ingredients is demonstrated by over 15 years of scientific research. According to the FTC's complaint, these claims are false or unsubstantiated.

According to the FTC, the defendants began marketing CortiStress in September 2003, through a nationally disseminated infomercial, also featuring Cynaumon and Talbott, that aired on a number of television channels, including TVN Direct. The FTC alleges that the defendants promoted cortisol control as "perhaps the most important aspect" of reducing health and disease risks.

According to the FTC's complaint, the defendants' infomercial claimed that persistently elevated levels of cortisol are the underlying cause of "every modern lifestyle disease that is associated with this fast-paced 21st century lifestyle" and also claimed that CortiStress controls cortisol and thus should be taken "for as long as you want to have good health." The FTC alleges that the defendants claimed that CortiStress reduces the risk of, or prevents, conditions such as osteoporosis, obesity, diabetes, Alzheimers' disease, cancer, and cardiovascular disease. According to the FTC's complaint, these claims are false or unsubstantiated.

The FTC's complaint also alleges that the defendants produced their infomercials for CortiSlim and CortiStress to look like episodes of a talk show called "Breakthroughs." According to the complaint, the "Breakthroughs" logo appears in the lower right-hand corner of the screen throughout one of the CortiSlim infomercials.

The infomercials do not indicate or otherwise reveal that Talbott and Gregory Cynaumon, the "host," are part of a joint venture to create, manufacture, and market CortiSlim and CortiStress. When a toll-free telephone number appears on-screen, Cynaumon, who is also named in the FTC's complaint, presents the number for "more information" and states that callers who mention the "Breakthroughs" program will receive a special discount.

According to the complaint, when the toll-free number appears on-screen, no oral or written disclaimer is provided to indicate that "Breakthroughs" is, in fact, a paid advertisement for CortiSlim or CortiStress; rather, the paid advertisement disclaimers appear only at the very beginning and very end of the infomercials.

The complaint signals the Commission's continuing concern about the use of deceptive format in infomercials, and this is the second recent case to include an allegation that the format of the infomercial misleads consumers. In July 2004, the Commission filed charges, including a deceptive format charge, against the marketers of a product called "Supreme Greens with MSM." In that case, the Commission won a preliminary injunction that prohibits efficacy claims for the product and requires clear "paid advertising" disclosures in any future infomercial advertising.

FDA Warning

The U.S. Food and Drug Administration (FDA) also has taken regulatory action against the marketers of CortiSlim. On August 19, 2004, the FDA sent a warning letter to Stephen Cheng and Window Rock Enterprises, Inc., stating that the dietary supplement CortiSlim is misbranded and violates the provisions of the Federal Food, Drug, and Cosmetic Act (the Act).

According to the FDA's letter, CortiSlim's label and accompanying information make unsubstantiated claims that CortiSlim "eliminates cravings," "controls appetite," "burn[s] calories more efficiently and naturally through thermogenesis," and "diminishe[s] hunger and stress eating." The FDA also asserts that claims that CortiSlim "supports healthy cortisol levels" or "supports weight maintenance efforts" would be unsubstantiated. FDA further expressed to the firm that if prompt action to correct these violations was not taken, enforcement action may be initiated without further notice.

"We will take appropriate enforcement action against firms that promote dietary supplement products with unsubstantiated claims about the benefits of the product," said Dr. Lester M. Crawford, Acting FDA Commissioner. "Consumers rely on the claimed benefits of the product, and we owe it to them that such claims be supported by competent and reliable scientific evidence."

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

Back to the top |

Terms of Use Your use of this site constitutes acceptance of the Terms of Use

Advertisements on this site are placed and controlled by outside advertising networks. ConsumerAffairs.com does not evaluate or endorse the products and services advertised. See the FAQ for more information.

Company Response Welcome If complaints about your company appear on our site, we welcome your response. Please see the Response Form for more information.

For more information, see the FAQ and privacy policy. The information on this Web site is general in nature and is not intended as a substitute for competent legal advice.  ConsumerAffairs.com Inc. makes no representation as to the accuracy of the information herein provided and assumes no liability for any damages or loss arising from the use thereof. 

Copyright © 2003-2009 ConsumerAffairs.com Inc.  All Rights Reserved.    The contents of this site may not be republished, reprinted, rewritten or recirculated without written permission.